Skip to main content

RSV Vaccination Effective Against Hospitalization in Patients 60 Years and Older

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 6, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Sept. 5, 2024 -- For older adults, respiratory syncytial virus (RSV) vaccination is effective against RSV hospitalization, according to a study published online Sept. 4 in the Journal of the American Medical Association.

Diya Surie, M.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues examined RSV vaccine effectiveness (VE) against RSV-associated hospitalization among adults aged 60 years and older. Adults hospitalized with acute respiratory illness at one of 24 hospitals in 19 U.S. states participating in a surveillance network from Oct. 1, 2023, to March 31, 2024, were eligible for inclusion in the study. Data were analyzed for 367 RSV case patients and 2,611 control patients, all aged 60 years and older.

The researchers found that 72.9 percent of the RSV case patients with known RSV subtype were RSV B. Overall, nine case patients and 256 control patients were vaccinated (2.5 versus 9.8 percent), with a median of 84 days between vaccination and illness onset. Vaccinated patients were more frequently older, White, and immunocompromised, were more likely to have outpatient visits in the past year, and were more likely to live in communities with a lower Social Vulnerability Index score compared with unvaccinated patients. VE against RSV hospitalization was 75 percent, with no difference seen when estimated with inverse probability of vaccination weighting or among adults aged 60 to 74 years or those aged 75 years and older (79, 75, and 76 percent, respectively).

"Among adults aged 60 years and older in 19 U.S. states, RSV vaccination was associated with a reduced likelihood of hospitalization with RSV compared with no vaccination," the authors write. "This study provides initial data to inform ongoing risk-benefit analyses of RSV vaccines for older adults."

One author disclosed ties to Syneos Health.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted September 2024

Read this next

RSV Vaccines, Nirsevimab Tied to Reduced RSV-Linked Hospitalization

TUESDAY, May 13, 2025 -- Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among...

Nirsevimab Effective for Reducing Burden of RSV in Infants

THURSDAY, May 8, 2025 -- Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings, according to a study published...

72 Percent of Infants Immunized Against Respiratory Syncytial Virus

TUESDAY, May 6, 2025 -- In a recent study of a population of infants, published online May 6 in Pediatrics, 72 percent of infants were found to be immunized against respiratory...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.